The telescope implant aims to improve visual acuity and quality of life for suitable patients with bilateral end-stage age-related macular degeneration. End-stage AMD is uncorrectable by any other treatment. The implant received approval from the U.S. Food and Drug Administration for patients living with end-stage AMD who are age 65 or older.
The telescope prosthesis is surgically implanted monocularly in the capsular bag after removal of the eye's lens. It employs wide-angle micro-optical lenses in a Galilean telescope design. The device can be implanted in an outpatient procedure.
The implant is the integral component of VisionCare Ophthalmic Technologies' comprehensive treatment program called CentraSight, which helps patients follow the steps necessary for proper diagnosis, surgical evaluation, implantation and postoperative care.
More articles on devices:
24 spine devices receive FDA 510(k) clearance in October
Centinel Spine to launch Ti-ACTIVE titanium coating
SI-BONE to host SI joint disorder symposium at NASS meeting